A standard and reliable methodology was used to synthesize the chloride benzimidazolium symmetric salt 1,3-bis(2-tert-butoxy-2-oxoethyl)-1H-benzimidazol-3-ium chloride, [(AcO-t-Bu)2BzIm]Cl (1) by employing 1H-benzimidazole and tert-butyl 2-chloroacetate as starting materials. Following the silver oxide route, the compound [{Ag(μ-Cl)(NHC)}2] (2) {NHC = (AcO-t-Bu)2BzIm} was obtained as a dimer, and through transmetalation reactions from [AuCl(SMe2)], two benzimidazolylidene N–heterocyclic carbene gold complexes were obtained using different stoichiometric ratios. Complex [AuCl(NHC)] (3) is a monocarbene species, while [Au(NHC)2][AgCl2] (4) is a biscarbene gold complex having a dichloroargentate anion. All complex structures have been elucidated through multinuclear NMR, FT-IR spectroscopy, HRMS, and single-crystal X-ray crystallography.The antibacterial capacity of the synthesized metallic compounds was evaluated in vitro versus Gram-positives, S. aureus, B. subtilis, and E. faecalis, and Gram-negatives, P. aeruginosa, E. coli, and S. typhi bacteria by Kirby-Bauer and MIC methods. The Kirby-Bauer experiments revealed that all compounds exhibited good antibacterial activity versus all bacterial strains. Silver compound 2 showed higher results against E. faecalis, P. aeruginosa, and S. typhi than the antibiotic. Gold complex 3 showed the highest antibacterial activity versus S. aureus and intermediate activity versus E. faecalis and S. typhi, and compound 4 showed only its best inhibition effect against E. faecalis and S. typhi and a slight upgrade against P. aeruginosa, revealing that no significant differences are having the two kinds of metal atoms. The preliminary results of MIC values for the bacteria tested were 8-13 μg/ml for 2 and 9-16 μg/ml for 3.
Read full abstract